^
    Back
    Association details:
    Biomarker:ATM S1905Ifs*25 + STK11 K262Sfs*25
    Cancer:Gallbladder Cancer
    Drug:Lynparza (olaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    The Oncologist
    Title:

    Effectiveness of Olaparib Treatment in a Patient with Gallbladder Cancer with an ATM-Inactivating Mutation

    Published date:
    02/11/2020
    Excerpt:
    ...recurrence of gallbladder carcinoma (GBC) in a patient...ATM S1905Ifs*25 and STK11 K262Sfs*25 mutations were detected...He was treated with olaparib based on the medical evidence and obtained a 13‐month PFS.
    DOI:
    10.1634/theoncologist.2019-0498